Filing Flows › Biodesix (BDSX) › Q4 2025
Biodesix (BDSX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Biodesix (BDSX) reported revenue of $28.8M for the fourth quarter 2025 (Q4 2025), +41% from a year earlier and +32% from the quarter before. Operating margin was -6.8%, net loss $4.0M (13.8% of revenue).
Biodesix, Q4 2025: revenue $28.8M (+41% year over year), operating margin -6.8%, net loss $4.0M, operating cash flow $778K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.8M | +32% | +41% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$4.0M | — | — |
| Operating cash flow | $778K | — | — |
| Free cash flow | $692K | — | — |
What changed
Revenue was $28.8M in Q4 2025, up 41% year over year and up 32% from the previous quarter. Diagnostic Tests was the largest line at 87% of revenue.
Operating costs exceeded revenue by $2.0M, an operating margin of -6.8%. Total costs grew 13% against revenue growth of 41%. The fastest-growing cost line was Research & development (+19%). The quarter ended with a net loss of $4.0M, narrower than the previous quarter's $8.7M loss. Net interest and other expense of $2.0M was the main reason.
Operating cash flow was $778K. Non-cash charges added back $1.4M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $2.3M. Capital expenditures of $86K left free cash flow of $692K.
Questions
What was Biodesix's revenue in the fourth quarter 2025?
Biodesix (BDSX) reported revenue of $28.8M for the fourth quarter 2025 (Q4 2025), +41% from a year earlier and +32% from the quarter before.
Was Biodesix profitable in the fourth quarter 2025?
Operating loss was $2.0M (-6.8% of revenue) and net loss $4.0M.
Source: Biodesix 10-K on SEC EDGAR.